Title | Platelet-Activating Factor – PAF: the role of a new mediator in pathological conditions | |
Authors | Paolo Arese¹, Federico Bussolino¹, Paolo M. Biffignandi¹ and A. de Courten²1. University of Torino, Italy and 2. Scientific Dept., OM Laboratories Ltd., Geneva, Switzerland | |
Citation | Arese, P., Bussolino, F., Biffignadi, P. and de Courten, A.: Platelet-Activating Factor – PAF: the role of a new mediator in pathological conditions, Epitheorese Klin. Farmakol. Farmakokinet. 1(1): 33-38 (1987) | |
Publication Date | 1987-07 | |
Full Text Language | English | |
Order – Buy | Ηλεκτρονική Μορφή: pdf (10 €) – Digital Type: pdf (10 €)pharmakonpress[at]pharmakonpress[.]gr | |
Keywords | Platelet, PAF, effects, biosynthesis, activating factor. | |
Other Terms | review article | |
Summary | Platelet activating factor (PAF) is a newly discovered mediator which is liberated by stimulated cells like the platelets, the neutrophils and the endothelial cells. PAF exerts a variety of biological effects including: a potent increase in platelet aggregation, vascular permeability, cell migration and bronchospasm. Its chemical structure, biosynthesis, origin and pharmacological actions are discussed. Research studies suggest that PAF may be implicated in the pathogenesis of diabetic microangiopathy. So, agents that interfere with PAF-mediated effects may be of potential interest. Among other drugs, calcium dobesilate (Doxium) a vascular protector with antiplatelet effects, was also found to strikingly inhibit PAF production in a dose and time-dependent way. The use of this drug as a PAF antagonist may present a new therapeutic approach. | |
Αναφορές – References | 1. Douglas, W.W.: Autacoidi. In: Pharmacological basis of therapy. (Goodman, LS. and Gilman, A. eds), p. 716, Ed. Grasso, Bologna, 19822. Braquet, P.: Pharmacological effects of platelet activating factor. Paper presented at the 6th Int. Conference on prostaglandins and related compounds. Florence (Italy), June, 3-6, 1986
3. Snyder, F.: Chemical and biochemical aspects of platelet activating factor: a novel class of acetylated ether-linked choline-phospholipids. Med. Res. Rev. 5: ‘107 (1985) 4. Camussi, G., Aglietta, M., Malavasi, F., Tetta, C., Piacibello, W., Bussoli/io, F.: Platelet-activiting factor. In: Glomerular Injury 300 Years after Morgagni (Bertani, T., Remuzzi, G., eds), p. 89, Wichtig Ed., 1983 5. Bussolino, F„ Benveniste, J.: Pharmacological modula¬tion of platelet-activating factor (PAF) release from rabbit leucocytes. I. Role of cAMP. Immunology 40: 367 (1980) 6. Bussolino, F, Gremo, F., Tetta, C., Pescarmona, G.P., Camussi, G.: Production of Platelet-Activating Factor (PAF) from chick retina stimulated by neurotransmitters. The 6th Int. Conference on Prostaglandins and related compounds. Florence (Italy), Jone, 3-6, 1986 7. Bussolino, F„ Biffignandi, P.’, Arese, P.: Inhibitory effect of calcium dobesilate on the production of PAF by the EA 926 cell line. 4th European Conference on Clinical Haemorrheology, Siena, June, 20-25, 1985 8. Bussolino, F„ Arese, P.: Pharmacological modulation of PAF production from EA 926 cell line. International Symposium “Leukotrienes and PAF-acether 85”. Paris, Sept. 27, 1985 9. Camussi, G„ Aglietta, M., Malavasi, F., Tetta, C., Piaci- bello, W., Bussolino, F.: Platelet-activating factor release from human endothelial cells in culture. J. Immunol. 131: 2397 (1983) 10. Camussi, G., Bussolino, F., Tetta, C., Benveniste, J.. Vercellone, A.: Platelet-activating factor and glomerulonephritis. In: Hemostasis, Prostaglandins and Renal Disease (Remuzzi G, Mecca G., de Gaetano G., eds), p. 133, Raven Press, New York, 1980 11. Camussi, G., Bussolino, F., Tetta, C., Brusca, R., Ragni, R.: The binding of platelet-activating factor (PAF) to polymorphonuclear neutrophils (PNM) as a trigger of immune-induced PNM aggregation. Pan. Med. 22: 117 (1980) 12. Pace, C., Deeming, Κ., Sanjar, S., Morley, J.: Evidence favouring PAF, rather than leukotrienes, as the primary agency of asthma pathology. International Symposium “Leucotrienes et PAF-acether 85”, Paris 27 Sept. 1985 13. Braquet, P., Vidal, R., Braquet, M., Deby, C., Bourgain, R.H., Vergaftig, B.B.: Platelet-activating factor induces acute modification of the rabbit retinal vessels imitating human retinopathies. In: Platelet Activating Factor and Structurally Related Ether Lipids (J. Benveniste, B. Arnoux, eds), p. 223, Elsevier Science Publ., New York, 1983 14. Barras, J.P. and Graf, C:; Effects of medication on blood and plasma viscosity in diabetic subjects with retinopathy. In: Pathogenetic concepts of diabetic microangio- pathy (Georg Thieme Verlag, Eds), Volume Nr. 11, p. 120, 1981 15. Cunha-Vaz, S.G.: Studies on the pathophysiology of diabetic retinopathy. The blood-retinal barrier in diabetes. Diabetes 32 (Suppl. 2): 20 (1983) 16. Goto, Y., Kakizaki, M., Toyota, T., Oikawa, S., Oikawa, N., Yagihashi, S.: Inhibition of thickening of glomerular capillary basement membrane in spontaneously diabetic rats. In [Abe H., Hoshi M., eds): Diabetic Microangiopathy, p. 433, S. Karger, Basel, 1983 17. Krzywanck, H.J., Breddin, Κ.: Platelet aggregation as a risk factor in diabetic subjects. In: Pathogenetic concepts of diabetic microangiopathy (Georg Thieme Verlag, Eds), Volume Nr. 11, p. 11, 1981 18. Porta, M., Towsend, C., Clover, G.M, Nanson, M., Alderson, A.R., McCraw, A., Kohner, E.M.: Evidence for functional endothelial cell damage in early diabetic retinopathy. Diabetologia 20: 597 (1981) 19. Williamson, J.R., Gardner, R.A., Boylan, C.W., Carroll, G.L., Chang, Κ., Marvell, J.S., Gonen, B., Kilo, C., Tran- Son-Tay, R., Suter, S.P.: Microrrheologic investigation of erythrocyte deformability in diabetes mellitus. Blood 65: 283 (1985) 20. Doly, M., Braquet, P., Bonhomme, B.: Inhibition of PAF- acether-induced disturbances of electroretinograhic waves by specific PAF-acether antagonists. The 6th Inter. Conference on Prostaglandins and related compounds, Florence (Italy), June, 3-6, 1986 21. Bussolino,’ F., Aglietta, M., Sanavio, F., Stacchini, A., Lauri, D„ Camussi, G.: Alkylether phosphoglycerides modify calcium homeostasis into human endothelial cells. J. Immunol. 135: 2748 (1985) 22. Snyder, F., Blank, M.L., Lee, T.C., Malone, B., Robinson, M., Woodant, D.: Alkylacetylglycerols versus “acyr-PAF as precursors in PAF biosynthesis and the role of arachidonic acid. International Symposium “Leucotrienes et PAF-acether 85”, Paris, 27 Sept. 1985 23. Gtoviczki, P., Fowl, R.J., Holier, L.H., Dewanjee, M.K., Plate, G., Kaye, M.P.: Prevention of platelet deposition by ibuprofen and calcium dobesilate in expanded polytetrafluoroethylene vascular grafts. Am. J. Surg. 150: 589 (1985) 24. Michal, M., Giessinger, N.: Effect of calcium dobesilate and its interaction with aspirin on thrombus formation in vivo. Thrombosis Res. 40: 215 (1985) 25. Salama Benarroch, I., Brodsky, M., Rubinstein, A., Viggiano, C.( Salama, E.A.: Treatment of blood hyperviscosity with calcium dobesilate in patients with diabetic retinopathy. Ophthalmic Res. 17: 131 (1985) 26. Schmitz-Valckenberg, P.: Therapeutic consequences in diabetic retinopathy. Therapiewoche 34 (37): 5221 (1984) 27. Vojnikovic, B.: Hyperviscosity in whole blood, plasma and aqueous humor decreased by Doxium (calcium dobesilate) in diabetics with retinopathy and glaucoma: a double- blind controlled study. Ophthalmic Res. 16: 150 (1984). |
|
Relative Papers | Antiplatelet Drugs: Clinical Pharmacology and Pharmacokinetics Charalambos T. Plessas and Stavros T. Plessas |
Online ISSN 1011-6575
Άρθρα Δημοσιευμένα σε αυτό το Περιοδικό Καταχωρούνται στα:
- Chemical Abstracts
- Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Articles published in this Journal are Indexed or Abstracted in: • Chemical Abstracts • Elsevier’s Bibliographic Databases: Scopus, EMBASE, EMBiology, Elsevier BIOBASE SCImago Journal and Country Rank Factor
Συντακτικη Επιτροπή-Editorial Board
ΕΤΗΣΙΑ ΣΥΝΔΡΟΜΗ 1987 – ANNUAL SUBSCRIPTION 1987 | |
Γλώσσα Πλήρους Κειμένου – Full Text Language | Αγγλικά – English |
Παραγγελία – Αγορά – Order – Buy | Ηλεκτρονική Μορφή: pdf (70 €) – Digital Type: pdf (70 €)pharmakonpress[at]pharmakonpress[.]gr |
Έντυπη Μορφή (70 € + έξοδα αποστολής) Printed Type (70 € + shipping)pharmakonpress[at]pharmakonpress[.]gr |